Thyroid-stimulating hormone is associated with insulin resistance independently of body mass index and age in women with polycystic ovary syndrome

Human Reproduction

Volumn 24, Issue 11, 2009, Pages 2924-2930

  Mueller, A ^a   Schofl C ^a   Dittrich, R ^a   Cupisti, S ^a   Oppelt, P G ^a   Schild, R L ^a   Beckmann, M W ^a   Haberle L ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Hyperandrogenic syndrome; Insulin resistance; PCOS; Thyroid stimulating hormone

Indexed keywords

THYROTROPIN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; GROUPS BY AGE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; THYROID FUNCTION;

EID: 70350508895     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/dep285     Document Type: Article

References (58)

1. Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:737-754.
2. Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care 2003;26:3320-3325.
3. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 2004;89:453-462.
4. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006;91:4237-4245.
5. Bakker SJ, ter Maaten JC, Popp-Snijders C, Slaets JP, Heine RJ, Gans RO. The relationship between thyrotropin and low density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J Clin Endocrinol Metab 2001;86:1206-1211.
6. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J et al. Guidelines Committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-126.
7. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006;65:137-145.
8. Brabant G, Beck-Peccoz P, Jarzab B, Laurberg P, Orgiazzi J, Szabolcs I, Weetman AP, Wiersinga WM. Is there a need to redefine the upper normal limit of TSH? Eur J Endocrinol 2006;154:633-637.
9. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med 2000;160:526-534.
10. Chubb SA, Davis WA, Davis TM. Interactions among thyroid function, insulin sensitivity, and serum lipid concentrations: the Fremantle diabetes study. J Clin Endocrinol Metab 2005;90:5317-5320.
11. Cupisti S, Dittrich R, Binder H, Beckmann MW, Mueller A. Evaluation of biochemical hyperandrogenemia and body mass index in women presenting with amenorrhea. Exp Clin Endocrinol Diabetes 2007a; 115:298-302.
12. Cupisti S, Dittrich R, Binder H, Kajaia N, Hoffmann I, Maltaris T, Beckmann MW, Mueller A. Influence of body mass index on measured and calculated androgen parameters in adult women with hirsutism and PCOS. Exp Clin Endocrinol Diabetes 2007b;115:380-386.
13. Cupisti S, Kajaia N, Dittrich R, Duezenli H, Beckmann MW, Mueller A. Body mass index and ovarian function are associated with endocrine and metabolic abnormalities in women with hyperandrogenic syndrome. Eur J Endocrinol 2008;158:711-719.
14. Dallongeville J, Helbecque N, Cottel D, Amouyel P, Meirhaeghe A. The Gly16-.Arg16 and Gln27-.Glu27 polymorphisms of beta2-adrenergic receptor are associated with metabolic syndrome in men. J Clin Endocrinol Metab 2003;88:4862-4866.
15. Demers LM, Spencer CA. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin Endocrinol (Oxf) 2003;58:138-140.
16. Dimitriadis G, Mitrou P, Lambadiari V, Boutati E, Maratou E, Panagiotakos DB, Koukkou E, Tzanela M, Thalassinos N, Raptis SA. Insulin action in adipose tissue and muscle in hypothyroidism. J Clin Endocrinol Metab 2006;91:4930-4937.
17. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
18. Frederiksen L, Brødbaek K, Fenger M, Jørgensen T, Borch-Johnsen K, Madsbad S, Urhammer SA. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab 2002; 87:3989-3992.
19. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002; 26:883-896.
20. Geisthövel F, Rabe T. The ESHRE/ASRM consensus on polycystic ovary syndrome (PCOS)-an extended critical analysis. Reprod Biomed Online 2007;14:522-535.
21. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005;90:581-585. (Pubitemid 40116712)
22. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87:489-499.
23. Janssen OE, Mehlmauer N, Hahn S, Offner AH, Gärtner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004;150:363-369.
24. Kajaia N, Binder H, Dittrich R, Oppelt PG, Flor B, Cupisti S, Beckmann MW, Mueller A. Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 2007;157:499-507.
25. Koritschoner NP, Alvarez-Dolado M, Kurz SM, Heikenwälder MF, Hacker C, Vogel F, Muñoz A, Zenke M. Thyroid hormone regulates the obesity gene tub. EMBO Rep 2001;2:499-504.
26. Larson J, Anderson EH, Koslawy M. Thyroid disease: a review for primary care. J Am Acad Nurse Pract 2000;12:226-232.
27. Levine JA, Nygren J, Short KR, Nair KS. Effect of hyperthyroidism on spontaneous physical activity and energy expenditure in rats. J Appl Physiol 2003;94:165-170.
28. Maratou E, Hadjidakis D, Kollias A, Tsegka K, Peppa M, Alevizaki M Dr, Mitrou P, Lambadiari V, Boutati E, Nikzas D et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol 2009; 13 Jan [Epub ahead of print].
29. Mathur RS, Moody LO, Landgrebbe S, Williamson HO. Plasma androgens and sex hormone binding globulin in the evaluation of hirsute patients. Fertil Steril 1981;35:29-37.
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
31. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR, Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002;51:880-883.
32. Michalaki MA, Vagenakis AG, Leonardou AS, Argentou MN, Habeos IG, Makri MG, Psyrogiannis AI, Kalfarentzos FE, Kyriazopoulou VE. Thyroid function in humans with morbid obesity. Thyroid 2006;16:73-78.
33. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952-960.
34. Möhlig M, Jürgens A, Spranger J, Hoffmann K, Weickert MO, Schlösser HW, Schill T, Brabant G, Schüring A, Pfeiffer AF et al. The androgen receptor CAG repeat modifies the impact of testosterone on insulin resistance in women with polycystic ovary syndrome. Eur J Endocrinol 2006;155:127-130.
35. Mueller A, Cupisti S, Binder H, Hoffmann I, Beckmann MW, Dittrich R. The role of albumin in the calculation of free and bioavailable testosterone in women with hyperandrogenemia. In Vivo 2006a;20:403-407.
36. Mueller A, Dittrich R, Binder H, Hoffmann I, Beckmann MW, Cupisti S. Evaluation of recommended markers for assessing hyperandrogenemia in women classified as having polycystic ovary syndrome (PCOS) according to the revised 2003 diagnostic criteria. Eur J Med Res 2006b;11:540-544.
37. Mueller A, Dittrich A, Cupisti S, Beckmann MW, Binder H. Is it necessary to measure free testosterone to assess hyperandrogenemia in women? The role of calculated free and bioavailable testosterone. Exp Clin Endocrinol Diabetes 2006c;114:182-187.
38. Mueller A, Cupisti S, Binder H, Hoffmann I, Kiesewetter F, Beckmann MW, Dittrich R. Endocrinological markers for assessment of hyperandrogenemia in hirsute women. Horm Res 2007;67:35-41.
39. Mueller A, Gooren LJ, Naton-Schötz S, Cupisti S, Beckmann MW, Dittrich R. Prevalence of polycystic ovary syndrome (PCOS) and hyperandrogenemia in female-to-male transsexuals. J Clin Endocrinol Metab 2008;93:1408-1411.
40. Nestler JE. Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 2000;24:S71-S73.
41. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685-697.
42. Ortiga-Carvalho TM, Oliveira KJ, Soares BA, Pazos-Moura CC. The role of leptin in the regulation of TSH secretion in the fed state: in vivo and in vitro studies. J Endocrinol 2002;174:121-125.
43. Poppe K, Glinoer D. Thyroid autoimmunity and hypothyroidism before and during pregnancy. Hum Reprod Update 2003;9:149-161.
44. Poppe K, Velkeniers B, Glinoer D. Thyroid disease and female reproduction. Clin Endocrinol (Oxf) 2007;66:309-321.
45. Reinehr T, Andler W. Thyroid hormones before and after weight loss in obesity. Arch Dis Child 2002;87:320-323.
46. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab 2006;91:3088-3091.
47. Reinehr T, Isa A, de Sousa G, Dieffenbach R, Andler W. Thyroid hormones and their relation to weight status. Horm Res 2008;70: 51-147
48. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H. Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92: 405-413.
49. Souter I, Sanchez LA, Perez M, Bartolucci AA, Azziz R. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 2004;191:759-767.
50. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291:228-238.
51. Torrance CJ, Devente JE, Jones JP, Dohm GL. Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats. Endocrinology 1997;138:1204-1214.
52. Uzunlulu M, Yorulmaz E, Oguz A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr J 2007;54:71-76. (Pubitemid 46481674)
53. Vermeulen A, Verdonck L, Kaufmann JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672.
54. Völzke H, Lüdemann J, Robinson DM, Spieker KW, Schwahn C, Kramer A, John U, Meng W. The prevalence of undiagnosed thyroid disorders in a previously iodine-deficient area. Thyroid 2003;13:803-810.
55. Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC. Uncoupling protein-2 polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol Endocrinol Metab 2004;286:E1-E7.
56. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:162-168.
57. Yilmaz M, Bukan N, Ersoy R, Karakoç A, Yetkin I, Ayvaz G, Cakir N, Arslan M. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum Reprod 2005;20:2414-2420.
58. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992, 377-384.